Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 7Esophageal Squamous Cell Carcinoma 4Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Head and Neck Neoplasms 2Breast Neoplasms 2Advanced Breast Cancer 2Urinary Bladder Neoplasms 1Turcot syndrome 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1Recurrence 1Papillomavirus Infections 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Mouth Neoplasms 1Meningeal Carcinomatosis 1Locally Advanced or Metastatic GC and GCJ Adenocarcinoma 1

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Cancer Metastatic × toripalimab × 90 days × Clear all
NCT07040228 2026-05-18

A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center

Phase 1/2 Recruiting
23 enrolled
Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡